A1 Refereed original research article in a scientific journal
4-Year outcome of bioactive stents versus everolimus-eluting stents in acute coronary syndrome
Authors: Karjalainen PP, Niemelä M, Pietilä M, Sia J, de Belder A, Rivero-Crespo F, de Bruyne B, Nammas W
Publisher: TAYLOR & FRANCIS LTD
Publication year: 2016
Journal: Scandinavian Cardiovascular Journal
Journal name in source: SCANDINAVIAN CARDIOVASCULAR JOURNAL
Journal acronym: SCAND CARDIOVASC J
Volume: 50
Issue: 4
First page : 218
Last page: 223
Number of pages: 6
ISSN: 1401-7431
eISSN: 1651-2006
DOI: https://doi.org/10.1080/14017431.2016.1177198
Abstract
Objectives: The BASE-ACS trial demonstrated non-inferiority of titanium-nitride-oxide-coated bioactive stents (BAS), versus everolimus-eluting stents (EES), for major adverse cardiac events (MACE) at 1- and 2-year follow-up, in patients with acute coronary syndrome (ACS). We presented the 4-year outcome of the BASE-ACS trial.Design: We randomized 827 patients with ACS to receive either BAS (417) or EES (410). MACE was a composite of cardiac death, non-fatal myocardial infarction (MI) or ischemia-driven target lesion revascularization (TLR) at 12-month follow-up. Analyses were performed by intention to treat. Follow-up was planned at 12 months, and yearly thereafter for 5 years.Results: Four-year clinical follow-up was completed in 753 (91.1%) patients. At 4 years, BAS were non-inferior to EES for MACE (14.7% versus 17.8%, respectively; p=0.24 for superiority; p=0.001 for non-inferiority). Non-fatal MI was less frequent with BAS (5.0% versus 9.2%, respectively; p=0.025). Cardiac death and ischemia-driven TLR were comparable (2.9% versus 3.5%, and 8.6% versus 9.2%; p=0.62 and p=0.80, respectively). Independent predictors of MACE were calcified lesions (HR 1.54, p=0.021), the number of vessels treated (HR 1.53, p=0.025), and reference vessel diameter (HR 0.54, p=0.006).Conclusions: In patients presenting with ACS, BAS was associated with a clinical outcome non-inferior to EES at 4-year follow-up.
Objectives: The BASE-ACS trial demonstrated non-inferiority of titanium-nitride-oxide-coated bioactive stents (BAS), versus everolimus-eluting stents (EES), for major adverse cardiac events (MACE) at 1- and 2-year follow-up, in patients with acute coronary syndrome (ACS). We presented the 4-year outcome of the BASE-ACS trial.Design: We randomized 827 patients with ACS to receive either BAS (417) or EES (410). MACE was a composite of cardiac death, non-fatal myocardial infarction (MI) or ischemia-driven target lesion revascularization (TLR) at 12-month follow-up. Analyses were performed by intention to treat. Follow-up was planned at 12 months, and yearly thereafter for 5 years.Results: Four-year clinical follow-up was completed in 753 (91.1%) patients. At 4 years, BAS were non-inferior to EES for MACE (14.7% versus 17.8%, respectively; p=0.24 for superiority; p=0.001 for non-inferiority). Non-fatal MI was less frequent with BAS (5.0% versus 9.2%, respectively; p=0.025). Cardiac death and ischemia-driven TLR were comparable (2.9% versus 3.5%, and 8.6% versus 9.2%; p=0.62 and p=0.80, respectively). Independent predictors of MACE were calcified lesions (HR 1.54, p=0.021), the number of vessels treated (HR 1.53, p=0.025), and reference vessel diameter (HR 0.54, p=0.006).Conclusions: In patients presenting with ACS, BAS was associated with a clinical outcome non-inferior to EES at 4-year follow-up.
UTU Research Portal